Stock Track | Labcorp Holdings Plunges 5.43% in Pre-market as Diagnostics Revenue Miss Weighs on Strong Q2 Results

Stock Track07-30

Shares of Labcorp Holdings Inc fell 5.43% in pre-market trading, even as the company reported better-than-expected second-quarter results and raised its full-year guidance. The decline suggests investors focused on a softer performance in the company's core diagnostics unit compared to a recently reported rival.

The company posted second-quarter revenue of $3.73 billion, slightly above the analyst consensus estimate of $3.71 billion, and adjusted earnings per share of $4.99, which topped expectations of $4.78. Labcorp also raised its 2026 adjusted earnings forecast to a range of $18.10 to $18.55 per share, with the midpoint exceeding Wall Street estimates.

However, according to a Reuters report citing Leerink Partners analyst Michael Cherny, investor focus was drawn to weaker-than-expected organic growth in the Diagnostics Laboratories segment. Revenue in this unit grew 5.5% to $2.90 billion, slightly missing the analyst estimate of $2.91 billion. This miss came after rival Quest Diagnostics raised its own forecast the previous week, setting a higher performance bar for the sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1159715328?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 20:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159715328","market":"nz","top_or_hot":-1,"title":"Stock Track | Labcorp Holdings Plunges 5.43% in Pre-market as Diagnostics Revenue Miss Weighs on Strong Q2 Results","media":"Stock Track","content":"<p>Shares of Labcorp Holdings Inc fell 5.43% in pre-market trading, even as the company reported better-than-expected second-quarter results and raised its full-year guidance. The decline suggests investors focused on a softer performance in the company's core diagnostics unit compared to a recently reported rival.</p>\n        <p>The company posted second-quarter revenue of $3.73 billion, slightly above the analyst consensus estimate of $3.71 billion, and adjusted earnings per share of $4.99, which topped expectations of $4.78. Labcorp also raised its 2026 adjusted earnings forecast to a range of $18.10 to $18.55 per share, with the midpoint exceeding Wall Street estimates.</p>\n        <p>However, according to a Reuters report citing Leerink Partners analyst Michael Cherny, investor focus was drawn to weaker-than-expected organic growth in the Diagnostics Laboratories segment. Revenue in this unit grew 5.5% to $2.90 billion, slightly missing the analyst estimate of $2.91 billion. This miss came after rival Quest Diagnostics raised its own forecast the previous week, setting a higher performance bar for the sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Labcorp Holdings Plunges 5.43% in Pre-market as Diagnostics Revenue Miss Weighs on Strong Q2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Labcorp Holdings Plunges 5.43% in Pre-market as Diagnostics Revenue Miss Weighs on Strong Q2 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-30 20:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Labcorp Holdings Inc fell 5.43% in pre-market trading, even as the company reported better-than-expected second-quarter results and raised its full-year guidance. The decline suggests investors focused on a softer performance in the company's core diagnostics unit compared to a recently reported rival.</p>\n        <p>The company posted second-quarter revenue of $3.73 billion, slightly above the analyst consensus estimate of $3.71 billion, and adjusted earnings per share of $4.99, which topped expectations of $4.78. Labcorp also raised its 2026 adjusted earnings forecast to a range of $18.10 to $18.55 per share, with the midpoint exceeding Wall Street estimates.</p>\n        <p>However, according to a Reuters report citing Leerink Partners analyst Michael Cherny, investor focus was drawn to weaker-than-expected organic growth in the Diagnostics Laboratories segment. Revenue in this unit grew 5.5% to $2.90 billion, slightly missing the analyst estimate of $2.91 billion. This miss came after rival Quest Diagnostics raised its own forecast the previous week, setting a higher performance bar for the sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LH","symbol_name":"徕博科","start_time":0,"source_url":"","article_id":"1159715328","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159715328","pubTimestamp":1785413547,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Labcorp Holdings Inc fell 5.43% in pre-market trading, even as the company reported better-than-expected second-quarter results and raised its full-year guidance. The decline suggests...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LH":"徕博科"},"translate_title":"股票跟踪 | Labcorp Holdings 盘前暴跌 5.43%，诊断收入未达预期拖累第二季度业绩强劲","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":1},"content_text":"Shares of Labcorp Holdings Inc fell 5.43% in pre-market trading, even as the company reported better-than-expected second-quarter results and raised its full-year guidance. The decline suggests investors focused on a softer performance in the company's core diagnostics unit compared to a recently reported rival.\nThe company posted second-quarter revenue of $3.73 billion, slightly above the analyst consensus estimate of $3.71 billion, and adjusted earnings per share of $4.99, which topped expectations of $4.78. Labcorp also raised its 2026 adjusted earnings forecast to a range of $18.10 to $18.55 per share, with the midpoint exceeding Wall Street estimates.\nHowever, according to a Reuters report citing Leerink Partners analyst Michael Cherny, investor focus was drawn to weaker-than-expected organic growth in the Diagnostics Laboratories segment. Revenue in this unit grew 5.5% to $2.90 billion, slightly missing the analyst estimate of $2.91 billion. This miss came after rival Quest Diagnostics raised its own forecast the previous week, setting a higher performance bar for the sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1159715328","isCrawlerRequest":true}